XENE Xenon Pharmaceuticals Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: neuroscience-focused biopharma discovering and commercializing novel ion channel modulators for neurological and psychiatric disorders
• • New emphasis on azetukalner in Phase 3 for epilepsy (FOS and PGTCS) and depression (MDD and BPD), with multiple late-stage studies ongoing
• • Strategic shift: advancing first Kv7 potassium channel opener with potential rapid onset and once-daily dosing, targeting difficult-to-treat epilepsy and neuropsychiatric indications
• • Notable metric: 380 patients enrolled in pivotal Phase 3 FOS study (X-TOLE2), seizure reduction up to 52.8% at 25 mg dose, ongoing 7-year open label extension with 46% retention at 48 months
• • Early-stage pipeline expansion into pain with initiation of Phase 1 studies for two novel candidates targeting Nav1.7 and Kv7 channels, exploiting genetic validation for new pain treatments

Risk Factors

• • Regulatory risk: alignment with Japan’s PMDA to enroll ~60 of 360 X-TOLE3 participants in Japan, affecting regulatory submission timing
• • Macroeconomic risk: foreign exchange exposure to Canadian dollar fluctuations impacting monetary assets and liabilities
• • Operational risk: reliance on successful completion of late-stage Phase 3 clinical trials for azetukalner, including X-TOLE2 topline data expected March 2026
• • Competitive risk: collaboration with Neurocrine Biosciences on NBI-921355, targeting epilepsy, poses potential competitive or partnership dependency risks
• • Financial risk: accumulated deficit $1.245 billion, net losses increasing to $345.9 million in 2025, requiring ongoing equity/debt financing with no product sales revenue yet

Management Discussion & Analysis

• • Revenue and profitability details not disclosed in provided section
• • No segment performance data available
• • Cash flow, buybacks, dividends, or capital expenditure figures not included
• • Forward-looking statements involve risks and uncertainties, no specific guidance or outlook provided

What are the latest XENE SEC filings in 2026?

Xenon Pharmaceuticals Inc. (XENE) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did XENE file its most recent 10-K annual report?

Xenon Pharmaceuticals Inc. (XENE) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view XENE 10-Q quarterly reports?

Xenon Pharmaceuticals Inc. (XENE)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every XENE 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has XENE filed recently?

Xenon Pharmaceuticals Inc. (XENE)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find XENE insider trading activity (Form 4)?

SignalX aggregates every XENE Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does XENE file with the SEC?

Xenon Pharmaceuticals Inc. (XENE) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new XENE filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Xenon Pharmaceuticals Inc. (XENE).

What is XENE's SEC CIK number?

Xenon Pharmaceuticals Inc. (XENE)'s SEC CIK (Central Index Key) number is 1582313. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1582313 to look up all XENE filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find XENE return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Xenon Pharmaceuticals Inc. (XENE) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.